Safety and efficacy of a milk-derived extract in the treatment of plaque psoriasis: an open-label study.
BACKGROUND
XP-828L is a nutraceutical compound obtained by the extraction of a growth factors-enriched protein fraction from bovine milk. XP-828L may improve psoriasis.


OBJECTIVE
An open-label study was performed to determine the efficacy, tolerability and safety of XP-828L in the treatment of plaque psoriasis.


METHODS
Eleven adult patients with chronic, stable plaque psoriasis on 2% or more of body surface area (BSA) received 5 g of oral XP-828L twice daily for 56 days.


RESULTS
All 11 patients completed the 56 days of treatment. At day 28, 6 of the 11 patients showed a reduction in PASI score. At 56 days, seven subjects had a decrease in PASI score ranging from 9.5% to 81.3%. Eight (8) out of 11 patients agreed to participate in an additional 8-week extension treatment phase. Improvement of psoriasis was maintained during the extension period. No clinically significant adverse events or laboratory abnormalities occurred.


CONCLUSIONS
XP-828L may improve psoriasis in patients with mild-to-moderate psoriasis.
Poulin
Y
Y
Centre de Recherche Dermatologique du Québec métropolitain (CRDQ), Québec, Canada, poulinyves@videotron.ca
Pouliot
Y
Y
Lamiot
E
E
Aattouri
N
N
Gauthier
S F
SF
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007136:Immunoglobulins; D007258:Informed Consent; D007768:Lactalbumin; D007781:Lactoferrin; D008297:Male; D008875:Middle Aged; D008894:Milk Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D011565:Psoriasis / Q000175:diagnosis / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome
D007136:Immunoglobulins; D008894:Milk Proteins; D007768:Lactalbumin; D007781:Lactoferrin